Newsletter | November 4, 2024

11.04.24 -- AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development

SPONSOR

A Full-Service Solution Partner Disrupting the Outsourcing Paradigm

inSeption Group offers a full-service solution designed to disrupt the current outsourcing paradigm, resurrecting a common-sense approach to rebuild business trust and confidence in a client’s selected vendor. Primarily focused on oncology, hematology, neurodegenerative disorders, and rare/orphan disease indications, with a specialization in cell and gene therapy, inSeption has been a solution for its’ clients who have experienced the progressive degradation of today’s outsourcing options. Contact them.

FEATURED ARTICLE

AI, PoS, And ROI: An Alphabet Soup Of 21st Century Drug Development

Part two of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI tools improve the probability of success and likelihood of drug approval.

INDUSTRY INSIGHTS

Deciphering Fiction From Reality In The Technology B2B Sell Cycle

Gain insight from someone who has worked on both sides of B2B sales about choosing a technology partner and what you should look for in a vendor.

How To Establish Effective, Scalable Drug Safety Ops Across Vendors

Numerous factors impact a drug safety program, but proper management of three key elements drives success while creating a scalable drug safety model.

Accelerating Your New Therapies Path To Market With Automation

Automation has become an essential tool for addressing the inefficiencies in traditional clinical trial methodologies, enabling trial teams to instead concentrate on critical tasks such as patient care.

Reducing ADC Timelines With Integrated Development And Manufacturing

ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.